Transforming growth factor-β and multidrug resistance in chronic lymphocytic leukemia

Medical Oncology

Volumn 16, Issue 2, 1999, Pages 110-118

  Friedenberg, William R ^a,b   Salzman, Sherry A ^a   Phan, Sonja M ^a   Burmester, James K ^a  

^a MARSHFIELD CLINIC   (United States)

^b GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

Blood disease; Crosslinking; Growth factors; Plasma levels; Receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PENTOSAN POLYSULFATE; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; AMINO ACID ANALYSIS; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032796064     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02785844     Document Type: Article

References (40)

1. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992; 119: 1017.
2. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995; 55: 1452.
3. Bursch W et al. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis. Br J Cancer 1993; 67: 531.
4. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-β. Blood 1997; 89: 941.
5. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncol 1993; 4: 493.
6. 1 arrest. p53 and Rb. Cancer Res 1996; 56: 3645.
7. Hopkin K. The TGF-β signaling pathway: a new model with no middle. J NIH Res 1994; 6: 40.
8. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996; 7: 93.
9. Marx J. DNA repair defect tied to mutated TGF-β receptor gene. Science 1995; 268: 1276.
10. Massagué J et al. Transforming growth factor-β. Cancer Surv 1992; 12: 81.
11. McCartney-Francis NL, Wahl SM. Transforming growth factor β: a matter of life and death. J Leukoc Biol 1994; 55: 401.
12. Serra R, Moses HL. Tumor suppressor genes in the TGF-β signaling pathway? Nat Med 1996; 2: 390.
13. Teicher BA et al. Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int J Cancer 1997; 71: 49.
14. Teicher BA, Holden SA, Ara G, Chen G. Transforming growth factor-β in in vivo resistance. Cancer Chemother Pharmacol 1996; 37: 601.
15. Urashima M et al. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells. Blood 1996; 87: 1928.
16. 2/ADM. Leukemia 1997; 11: 894.
17. Kehrl JH et al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137: 3855.
18. Kehrl JH et al. Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol 1989; 143: 1868.
19. Israels LG et al. Role of transforming growth factor-β in chronic lymphocytic leukemia. Leukemia Res 1993; 17: 81.
20. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor β as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994; 179: 999.
21. Markowitz S et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336.
22. Kakeji Y, Teicher BA. Induction of transforming growth factor-β (TGF-β) by cytotoxic anticancer therapies and its potential role in the development of therapeutic resistance. Proc Am Assoc Cancer Res 1996; 37: 35.
23. DeCoteau JF et al. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 5877.
24. Yasumi K et al. Transforming growth factor β type II receptor (TGFβRII) mutation in gastric lymphoma without mutator phenotype. Pathol Int 1998; 48: 134-137.
25. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor β receptor expression in murine plasmacytomas. Proc Natl Acad Sci USA 1998; 95: 189-194.
26. De M et al. Functional characterization of transforming growth factor β type II receptor mutants in human cancer. Cancer Res 1998; 58: 1986-1992.
27. Pasche B et al. Type I transforming growth factor β receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res 1998; 58: 2727-2732.
28. Cumber PM et al. Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia. Br J Haematol 1990; 76: 226.
29. El Rouby S et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452.
30. Friedenberg WR et al. Multi-drug resistance in chronic lymphocytic leukemia. Leuk Lymph (in press).
31. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990; 82: 1133.
32. Holmes JA et al. Is the MDR1 gene relevant in chronic lymphocytic leukemia? Leukemia 1990; 4: 216.
33. Ludescher C et al. Activity of p-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751.
34. Michieli M et al. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br J Haematol 1991; 77: 460.
35. Shustik C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 1991; 79: 50.
36. 3 multidurg-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496.
37. Sparrow RL, Hall FJ, Siregar H, Van Der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 1993; 17: 941.
38. Rochlitz CF et al. PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia. Ann Hematol 1992; 65: 241-246.
39. Wallner J et al. MDR1 gene expression in chronic lymphocytic leukemia. Leuk Lymph 1994; 13: 333-338.
40. Beck WT et al. Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-3020.